KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Pacira BioSciences (PCRX) Other Gross PP&E Adjustments (2016 - 2026)

Pacira BioSciences has reported Other Gross PP&E Adjustments over the past 16 years, most recently at $198.6 million for Q1 2026.

  • For Q1 2026, Other Gross PP&E Adjustments fell 6.55% year-over-year to $198.6 million; the TTM value through Mar 2026 reached $198.6 million, down 6.55%, while the annual FY2025 figure was $236.6 million, 5.68% down from the prior year.
  • Other Gross PP&E Adjustments for Q1 2026 was $198.6 million at Pacira BioSciences, down from $236.6 million in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at $250.9 million in Q4 2024 and troughed at $163.2 million in Q1 2022.
  • A 5-year average of $215.0 million and a median of $213.6 million in 2023 define the central range for Other Gross PP&E Adjustments.
  • Biggest five-year swings in Other Gross PP&E Adjustments: grew 20.52% in 2022 and later dropped 6.55% in 2026.
  • Year by year, Other Gross PP&E Adjustments stood at $230.1 million in 2022, then rose by 7.86% to $248.2 million in 2023, then grew by 1.07% to $250.9 million in 2024, then dropped by 5.68% to $236.6 million in 2025, then decreased by 16.07% to $198.6 million in 2026.
  • Business Quant data shows Other Gross PP&E Adjustments for PCRX at $198.6 million in Q1 2026, $236.6 million in Q4 2025, and $221.5 million in Q3 2025.